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X-linked hypohidrotic ectodermal dysplasia (XLHED) is
the most common of the ectodermal dysplasias, present-
ing with hypohidrosis, hypodontia, hypotrichosis and
mucociliary gland hypoplasia. As an X-linked disorder,
the phenotype is more consistently severe in affected
males than in affected females and is associated with a
risk for serious and potentially life-threatening
hyperthermia and respiratory infections in early
childhood.
Although XLHED has been described in publications
since the mid 19th century, it was not until the geno-
mics revolution that the underlying cause was identi-
fied as a deficiency of the ectodermal morphogen
ectodysplasin. Over 200 mutations of the correspond-
ing gene, EDA, have been described that produce a
deficiency in the activity of its primary translational
product EDA-A1. As a key regulator of the initiation,
maturation and maintenance of ectodermal appen-
dages, the exact timing for EDA-A1 activity in devel-
opment may vary both between tissues and between
species. This was demonstrated in two animal models
of XLHED, the mouse and the dog, where a recombi-
nant form of EDA-A1 (EDI200) was administered
either antenatally or postnatally. Perhaps surprisingly,
in the dog model most analogous to human XLHED,
postnatal EDI200 administration was associated with a
sustained, reproducible and clinically meaningful cor-
rection of the XLHED phenotype.
Detailed studies of the response to EDI200 in both
animal models have provided a roadmap for clinical
trials involving EDI200 as an EDA-A1 replacement in
patients with XLHED. Under consideration for 2012 is
the initiation of studies in a small number of XLHED-
affected adults and newborns to confirm the safety of
EDI200 in these populations and to assess the potential
for ameliorating the clinical signs and symptoms. Key
aspects of this clinical development plan will be dis-
cussed including selection of dose and dosing regimen,
the window of efficacy and options for bioactivity
monitoring.
Published: 25 May 2012
doi:10.1186/1746-160X-8-S1-I18
Cite this article as: Huttner: EDI200 therapeutic trial. Head & Face
Medicine 2012 8(Suppl 1):I18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Edimer Pharmaceuticals, Cambridge, USA
Huttner Head & Face Medicine 2012, 8(Suppl 1):I18
http://www.head-face-med.com/content/8/S1/I18
HEAD & FACE MEDICINE
© 2012 Huttner; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
